Phase 1 Dose-Escalation Study of Pegylated Arginine Deiminase, Cisplatin, and Pemetrexed in Patients With Argininosuccinate Synthetase 1–Deficient Thoracic Cancers

PURPOSE: Pegylated arginine deiminase (ADI-PEG 20) depletes essential amino acid levels in argininosuccinate synthetase 1 (ASS1) –negative tumors by converting arginine to citrulline and ammonia. The main aim of this study was to determine the recommended dose, safety, and tolerability of ADI-PEG 20...

Descripción completa

Detalles Bibliográficos
Autores principales: Beddowes, Emma, Spicer, James, Chan, Pui Ying, Khadeir, Ramsay, Corbacho, Javier Garcia, Repana, Dimitra, Steele, Jeremy P., Schmid, Peter, Szyszko, Teresa, Cook, Gary, Diaz, Monica, Feng, Xiaoxing, Johnston, Amanda, Thomson, Jim, Sheaff, Michael, Wu, Bor-Wen, Bomalaski, John, Pacey, Simon, Szlosarek, Peter W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Clinical Oncology 2017
Materias:
ORIGINAL REPORTS
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6141244/
https://www.ncbi.nlm.nih.gov/pubmed/28388291
http://dx.doi.org/10.1200/JCO.2016.71.3230

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6141244/
https://www.ncbi.nlm.nih.gov/pubmed/28388291
http://dx.doi.org/10.1200/JCO.2016.71.3230

Ejemplares similares